66852-54-8Relevant academic research and scientific papers
A PROCESS FOR PREPARING A CRYSTALLINE FORM OF HALOBETASOL PROPIONATE
-
Page/Page column 25, (2008/06/13)
The present invention provides a process for preparing a crystalline form of halobetasol propionate, comprising the step of crystallizing halobetasol propionate from absolute ethanol or a mixture of ethanol and water, wherein the crystalline form of halobetasol propionate is characterized by an x-ray powder diffraction pattern having peaks at 10.0, 11.6, 12.9, 13.4, 14.5, 16.4, 17.6, and 23.5 + 0.2 degrees 2θ.
Crystalline forms of halobetasol propionate
-
Page 6, (2008/06/13)
The present invention provides a crystalline halobetasol propionate selected from the group consisting of halobetasol propionate having crystalline Form I characterized by power X-ray diffraction peak positions and intensities as set forth in Table 1 herein, halobetasol propionate having crystalline Form II characterized by power X-ray diffraction peak positions and intensities as set forth in Table 2 herein, halobetasol propionate having crystalline Form III characterized by power X-ray diffraction peak positions and intensities as set forth in Table 3 herein, halobetasol propionate having crystalline Form IV characterized by power X-ray diffraction peak positions and intensities as set forth in Table 4 herein, halobetasol propionate having crystalline Form V characterized by power X-ray diffraction peak positions and intensities as set forth in Table 5 herein, and halobetasol propionate having crystalline Form VI characterized by power X-ray diffraction peak positions and intensities as set forth in Table 6 herein.
Method for the preparation of 6alpha-fluoro corticosteroids
-
, (2008/06/13)
A method for producing a 6α-fluorinated corticosteroid or derivative thereof by reacting a 17-hydroxy-21-ester epoxide of Formula II with a stereoselective fluorinating agent to stereoselectively form a 21-ester-17-hydroxy 6α-fluorinated compound of Formula VII R1 can be OC(O)—Rd; R4 can be C(O)—Rd; R3 can be H or Rd. Each Rd may be the same or different and is independently selected from (C1-4)alkyl, aryl and heteroaryl. The dashed line can be a single or a double bond. R4 may be, for example, acetyl; R3 may be, for example, alpha or beta methyl; R4 may be, for example, acetate or propionate. The stereoselective fluorinating agent used in the reaction may be, for example, a fluoropyridinium or fluoroquinuclidium compound, for example, Selectfluor?.
Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
-
, (2008/06/13)
Methods for reducing or preventing transplant rejection in the eye of an individual are described, comprising: a) performing an ocular transplant procedure; and b) implanting in the eye a bioerodible drug delivery system comprising an immunosuppressive agent and a bioerodible polymer.
Composition for the topical treatment of poison ivy and other forms of contact dermatitis
-
, (2008/06/13)
Composition for topical administration comprising (a) a corticosteroid, and (b) a drying agent.
Polyhalogeno-steroids
-
, (2008/06/13)
Novel 6α,9α,21-trihalogeno-11β-hydroxy-16α or 16β-methyl-17α-propionyloxy-pregn-4-ene-3,20-dione compounds of the formula STR1 in which X represents chlorine or flourine, R represents the group --CH 2 CH--, --CH CH-- or --CH CCl--, the chlorine atom being in the positon 2 of the steroid numbering, and in which the 16-methyl radical is α- or β-oriented, are useful pharmaceuticals, especially anti-inflammatory agents for topical administration.
